Recap on InDex Pharmaceuticals and update on PK results with Cobitolimod.
Recap on InDex Pharmaceuticals and update on PK results with Cobitolimod.
CEO Jenny Sundqvist gave a very confident impression of why the Conclude phase lll study with Cobitolimod were delayed, how they will speed up the process and what potential triggers to look for in Q4-2023. Further the CEO confirmed earlier estimates for growth in the total addressable UC market.
CDO Dr. Eva Arlander deep dived into the recently announced outcome of the PK-study with Cobitolimod 500 mg dose and how they will use positive data going forward.
Listen to the interview: https://www.inderes.dk/videos/index-pharmaceuticals-update-on-recently-announced-results-of-pk-study-with-cobitolimod
Disclaimer:
HC Andersen Capital receives payment from InDex Pharmaceuticals for a Digital IR/Corporate Visibility subscription agreement. /ANALYST Claus Thestrup 09:35 AM 03-29-2023.
InDex Pharmaceuticals Holding
InDex Pharmaceuticals er en farmaceutisk udviklingsvirksomhed med fokus på immunologiske sygdomme, hvor der er et stort udækket medicinsk behov for nye behandlingsmuligheder. Virksomhedens førende aktiv er lægemiddelkandidaten cobitolimod, som er i et sent stadium i klinisk udvikling til behandling af moderat til svær colitis ulcerosa - en invaliderende, kronisk betændelse i tyktarmen. InDex har også udviklet en platform af patentbeskyttede stoffer i opdagelsesstadiet, såkaldte DNA-baserede ImmunoModulatory Sequences (DIMS), med potentiale til at blive brugt til behandling af forskellige immunologiske sygdomme. InDex er baseret i Stockholm, Sverige. Selskabets aktier (ticker INDEX) handles på Nasdaq First North Growth Market Stockholm.
Read more on company page